Invivyd, Inc. IVVD
Set alert
At close · Nov 2
After hours · Nov 2, 7:52 PM ET
- YTD
- -76.44%
- 1 year
- -66.93%
- Open
- 0.598
- Prev close
- 0.5817
- Mkt cap
- 171.55M
- Vol
- 4.43M
- Avg vol
- 5.09M
- EPS
- -0.33
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.55
- High
- 0.5995
- Forward P/E
- -2.36
- Beta
- 0.66
- Short ratio
- 23.71
- Inst. own
- 79.25%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 0.78992
- 200-d avg
- 1.55
- 1y target
- 5.89
5D chart
Signals (147)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 3:35 PM | 5 hours ago |
| SMA: Bullish | Nov 2, 3:35 PM | 5 hours ago |
| SMA: Bearish | Nov 2, 3:30 PM | 5 hours ago |
| SMA: Bearish | Nov 2, 3:30 PM | 5 hours ago |
| SMA: Bullish | Nov 2, 3:15 PM | 5 hours ago |
| SMA: Bearish | Nov 2, 3:10 PM | 5 hours ago |
| SMA: Bullish | Nov 2, 3:05 PM | 5 hours ago |
| MACD: Buy Signal | Nov 2, 3:00 PM | 5 hours ago |
| SMA: Bullish | Nov 2, 2:50 PM | 6 hours ago |
| SMA: Bearish | Nov 2, 2:45 PM | 6 hours ago |
| SMA: Bullish | Nov 2, 2:40 PM | 6 hours ago |
| SMA: Bearish | Nov 2, 1:35 PM | 7 hours ago |
| MACD: Sell Signal | Nov 2, 1:20 PM | 7 hours ago |
| SMA: Bearish | Nov 2, 1:10 PM | 7 hours ago |
| SMA: Bullish | Nov 2, 12:40 PM | 8 hours ago |
| SMA: Bearish | Nov 2, 12:35 PM | 8 hours ago |
| SMA: Bullish | Nov 2, 12:25 PM | 8 hours ago |
| SMA: Bearish | Nov 2, 12:15 PM | 8 hours ago |
| MACD: Buy Signal | Nov 2, 11:40 AM | 9 hours ago |
| SMA: Bullish | Nov 2, 11:35 AM | 9 hours ago |
| SMA: Bullish | Nov 2, 11:30 AM | 9 hours ago |
| SMA: Bearish | Nov 2, 10:50 AM | 10 hours ago |
| SMA: Bearish | Nov 2, 10:50 AM | 10 hours ago |
| SMA: Bullish | Nov 2, 10:35 AM | 10 hours ago |
| SMA: Bearish | Nov 2, 10:30 AM | 10 hours ago |
| MACD: Sell Signal | Nov 2, 10:30 AM | 10 hours ago |
| MACD: Buy Signal | Nov 2, 10:20 AM | 10 hours ago |
| SMA: Bullish | Nov 2, 10:10 AM | 10 hours ago |
| SMA: Bullish | Nov 2, 9:50 AM | 11 hours ago |
| SMA: Bearish | Nov 2, 9:45 AM | 11 hours ago |
| MACD: Sell Signal | Nov 2, 9:45 AM | 11 hours ago |
| SMA: Bearish | Nov 2, 9:30 AM | 11 hours ago |
| RSI: Overbought | Oct 30, 3:35 PM | 3 days ago |
| RSI: Overbought | Oct 30, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:55 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 2:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 2:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 2:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 2:15 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 1:45 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 1:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 12:45 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:35 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:20 PM | 3 days ago |
| SMA: Bullish | Oct 30, 11:55 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:35 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:15 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:45 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:35 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:55 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:40 PM | 4 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:45 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 2:40 PM | 4 days ago |
| RSI: Oversold | Oct 29, 1:45 PM | 4 days ago |
| RSI: Oversold | Oct 29, 1:15 PM | 4 days ago |
| RSI: Oversold | Oct 29, 12:35 PM | 4 days ago |
| SMA: Bearish | Oct 29, 11:55 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:50 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 11:25 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 11:00 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:15 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 10:15 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:10 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 9:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 28, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 28, 3:35 PM | 5 days ago |
| SMA: Bearish | Oct 28, 3:05 PM | 5 days ago |
| SMA: Bearish | Oct 28, 3:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 3:05 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:20 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 2:20 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:45 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:45 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:00 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:50 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:20 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 10:15 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:50 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 27, 3:55 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:55 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 3:55 PM | 6 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:30 PM | 6 days ago |
| SMA: Bullish | Oct 27, 3:25 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:20 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 6 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 2:00 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 1:50 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:45 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:30 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 1:25 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:00 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:00 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:10 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:10 PM | 6 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:00 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 6 days ago |
News
-
1 week ago benzinga.com
Invivyd Presents Preclinical Data Showing Measles Antibody Candidate VMS063 Demonstrates Potent Antiviral Activity Against Contemporary Measles Fusion Protein Variants
VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd VMS063 demonstrated potent in vitro antiviral activity against contemporary…
1 week ago globenewswire.com
Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd VMS063 demonstrated potent in vitro antiviral activity against contemporary…
-
2 weeks ago benzinga.com
Invivyd And SPEAR Study Group Initiate FLINTLOCK Phase 2 Trial Evaluating Safety, Tolerability, Pharmacokinetics, And Clinical Efficacy Of High-Dose Monoclonal Antibody VYD2311 In Individuals With Long COVID Or Post-Vaccination Syndrome
The Phase 2 FLINTLOCK clinical trial includes the following study features:Randomized, double-blind, placebo-controlled, proof-of-concept studyTests Invivyd’s monoclonal antibody VYD2311, an…
2 weeks ago globenewswire.com
Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
NEW HAVEN, Conn., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) and the SPEAR Study Group today announced the initiation of FLINTLOCK, a Phase 2 clinical trial evaluating the safety,…
4 weeks ago defenseworld.net
Invivyd’s VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval
Invivyd (NASDAQ: IVVD) reported topline results from its Phase III LIBERTY study of VYD2311, an investigational low-dose intramuscular monoclonal antibody designed to prevent COVID-19, and outlined…
4 weeks ago globenewswire.com
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on October 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase…
4 weeks ago marketbeat.com
Invivyd's VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval
Invivyd NASDAQ: IVVD reported topline results from its Phase III LIBERTY study of VYD2311, an investigational low-dose intramuscular monoclonal antibody designed to prevent COVID-19, and outlined…
1 month ago benzinga.com
Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody
Invivyd Inc. (NASDAQ:IVVD) on Tuesday announced topline results from its Phase 3 LIBERTY study of its investigational COVID-19 monoclonal antibody candidate.
1 month ago benzinga.com
Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody
Invivyd reported Phase 3 LIBERTY trial data for VYD2311, showing strong safety and enhanced COVID-19 antibody levels.
1 month ago seekingalpha.com
Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission Transcript
Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission Transcript
-
1 month ago benzinga.com
Invivyd Announces Clinically Meaningful And Statistically Significant Topline Data From Its LIBERTY Phase 3 Study Evaluating Safety And Tolerability Of VYD2311, COVID-19 vaccine COMIRNATY, And VYD2311 Co-Administered With mRNA-Based COVID-19 Vaccine
VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the…
1 month ago globenewswire.com
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, clinically meaningful, and statistically significant topline data from the LIBERTY Phase 3,…
1 month ago marketwatch.com
These beaten-down stocks could bounce back in January, if history is any guide
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular session. The company's market cap stands at $9.0 million. GRAIL (NASDAQ:GRAL) shares moved upwards by 31.47%…
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Greenland Mines (NASDAQ:GRML) stock rose 108.1% to $5.93 during Monday's pre-market session. The market value of their outstanding shares is at $9.0 million. Cue Biopharma (NASDAQ:CUE) stock…
1 month ago marketbeat.com
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
For small-cap biotech investors, a single date on the calendar can matter more than a quarter's worth of earnings reports. These companies often burn cash for years without product revenue, betting…
1 month ago globenewswire.com
Invivyd to Participate in Upcoming September Investor Conferences
NEW HAVEN, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc W. Elia, Chairman and Chief Executive Officer, and members of company management will…
1 month ago defenseworld.net
BlackRock Inc. Takes $14.08 Million Position in Invivyd, Inc. $IVVD
BlackRock Inc. bought a new stake in shares of Invivyd, Inc. (NASDAQ: IVVD) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission.…
2 months ago globenewswire.com
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on September 1, 2026, Invivyd granted six newly hired non-executive employees options to…
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers bioAffinity Technologies (NASDAQ:BIAF) shares increased by 68.4% to $7.68 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million. Lakewood-Amedex…
-
2 months ago benzinga.com
Invivyd Continues To Expect Top-Line Data From VYD2311 Program Around The End Of Q3 2026
Invivyd continues to expect top-line data from the VYD2311 program around the end of Q3 2026. At that time, Invivyd plans to either unblind the DECLARATION study in its entirety and submit a…
-
2 months ago benzinga.com
Invivyd Appoints Marc Elia As CEO
Mr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate strategyAjay Royan, Founder of Mithril Capital and a founding,…
2 months ago globenewswire.com
Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the company has appointed Marc Elia, current Chairman of the Invivyd Board of Directors, as…
-
2 months ago benzinga.com
Cantor Fitzgerald Reiterates Overweight on Invivyd, Maintains $10 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates Invivyd (NASDAQ:IVVD) with a Overweight and maintains $10 price target.
2 months ago zacks.com
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.12 per share a year ago.
2 months ago globenewswire.com
Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
NEW HAVEN, Conn., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the second quarter ended June 30, 2026, and recent business highlights.
3 months ago globenewswire.com
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on August 1, 2026, Invivyd granted ten newly hired non-executive employees options to purchase an…
-
3 months ago benzinga.com
The FDA Sent Invivyd An Advance Termination Notice For Pemgarda (Pemivibart) Emergency Use Authorization Following US Department Of Health And Human Services’ Announcement Of Advanced Notice Of Termination Of Covid-19 EUA Declaration On June 30, With Effective Date Of June 29, 2027
U.S. Department of Health and Human Services (HHS) announced advanced Notice of Termination of the COVID-19 EUA declaration, effective June 29, 2027 Consequently, Invivyd received from the U.S. Food…
3 months ago globenewswire.com
Invivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
NEW HAVEN, Conn., July 06, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has sent Invivyd a Notice of Termination for the…
4 months ago globenewswire.com
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., July 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on July 1, 2026, Invivyd granted 14 newly hired non-executive employees options to purchase an…
4 months ago globenewswire.com
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for…
-
4 months ago benzinga.com
Invivyd Completes Enrollment Phase 3 LIBERTY Trial Of Covid-19 Monoclonal Antibody VYD2311 With An mRNA Covid-19 Vaccine, Topline Data Expected in Q3 2026
Data from LIBERTY can provide important insight into the VYD2311 clinical profile by direct comparison between COVID antibody prophylaxis and COVID vaccine.LIBERTY is part of Invivyd's broader…
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Invivyd, Maintains $10 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Invivyd (NASDAQ:IVVD) with a Buy and maintains $10 price target.
-
4 months ago benzinga.com
Invivyd Dosed The First Participants In LIBERTY Phase 3 Trial Of VYD2311 Alone, And VYD2311 Co-administered With A Covid-19 Vaccine In Healthy Adults; Topline Data Is Expected In Q3 2026, To Accompany Anticipated Data From Pivotal DECLARATION Study
LIBERTY clinical trial will evaluate the comparative safety and tolerability of VYD2311 versus mRNA COVID-19 vaccine, as well as explore the safety and immunology of co-administered VYD2311 and mRNA…
-
5 months ago benzinga.com
Invivyd Completes Enrollment In DECLARATION Phase 3 Trial of VYD2311 To Prevent Symptomatic Covid-19; Top-line Data Expected In Approximately Late Q3 2026
DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of symptomatic COVID-19 versus placebo, at three months, from…
5 months ago benzinga.com
Gemini Space Posts Upbeat Q1 Results, Joins Figma, Sutro Biopharma And Other Big Stocks Moving Higher On Friday
Dow Jones falls 400 points, while Gemini Space Station Inc (NASDAQ: GEMI) sees 25.7% jump after strong financial results and $100M investment.
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
5 months ago benzinga.com
Invivyd Reports Q1 2026 Results: Full Earnings Call Transcript
Invivyd Reports Q1 2026 Results: Full Earnings Call Transcript
-
5 months ago benzinga.com
Invivyd Q1 EPS $(0.13) Misses $(0.07) Estimate, Sales $13.744M Miss $18.050M Estimate
Invivyd (NASDAQ:IVVD) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.07) by 85.71 percent. This is a 7.14 percent increase over losses of $(0.14)…
-
5 months ago benzinga.com
Invivyd EVADE Trial Data Reveals Monoclonal Antibody VYD2311 Demonstrates Minimal Tolerability Issues Versus COVID mRNA Vaccination
Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody adintrevimab from the EVADE study, demonstrating minimal tolerability issuesResults allow for…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
6 months ago benzinga.com
BlackBerry Posts Upbeat Q4 Results, Joins Constellation Brands, Marvell Technology And Other Big Stocks Moving Higher On Thursday
U.S. stocks fell, Dow Jones down 100+ points. BlackBerry (NYSE:BB) reported strong Q4 results and sales guidance. Shares rose 12.2%. Other top gainers: MGRT, STAA, FBRX, EOSE, MFI, SATL, IVVD, MRLN,…
6 months ago benzinga.com
Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program
Invivyd expands VYD2311 COVID study, delays timeline to Q3 2026, and advances measles antibody VMS063 toward clinical development.
-
6 months ago benzinga.com
Invivyd Announces Discovery And Advancement Of Measles Monoclonal Antibody Candidate For Treatment And Prevention Of Measles Discovered Using Its Proprietary Technology
Confirmed, pooled, blinded COVID-19 events in the ongoing Phase 3 DECLARATION study of VYD2311 accumulated to date (~ 50% of study progress) can already provide sufficient statistical power to…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
7 months ago benzinga.com
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session